Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SABS
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Michael Kramarz | 8.95M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Robert Egen Atkinson | 8.95M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Commodore Capital Master LP | 8.95M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Commodore Capital LP | 8.95M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | David Edward Johnson | 7.97M | 8.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Caligan Partners LP | 7.97M | 8.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Vivo Opportunity Cayman, LLC | 2.29M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Vivo Opportunity Cayman Fund, L.P. | 2.29M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Vivo Opportunity, LLC | 22.64M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Vivo Opportunity Fund Holdings, L.P. | 22.64M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 6.63M | 7.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Joseph Edelman | 6.63M | 7.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Perceptive Advisors LLC | 6.63M | 7.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Dmitry Balyasny | 7.23M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Dames GP LLC | 7.23M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Balyasny Asset Management Holdings LP | 7.23M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Bam GP LLC | 7.23M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Balyasny Asset Management L.P. | 7.23M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Woodline Partners LP | 5.46M | 6.8% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Phillip Gross | 6.41M | 8.4% | SCHEDULE 13G ↗ |
| Aug 12, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Robert Atchinson | 6.41M | 8.4% | SCHEDULE 13G ↗ |
| Aug 12, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Adage Capital Management, L.P. | 6.41M | 8.4% | SCHEDULE 13G ↗ |
| Aug 10, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 9.61M | 9.9% | SCHEDULE 13D/A ↗ |
| Aug 10, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Rajeev Shah | 9.61M | 9.9% | SCHEDULE 13D/A ↗ |
| Aug 10, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Peter Kolchinsky | 9.61M | 9.9% | SCHEDULE 13D/A ↗ |
| Aug 10, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Management, L.P. | 9.61M | 9.9% | SCHEDULE 13D/A ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | David Edward Johnson | 7.97M | 10.4% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Caligan Partners LP | 7.70M | 10.4% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 6.43M | 8.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Joseph Edelman | 6.43M | 8.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Perceptive Advisors LLC | 6.43M | 8.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Dmitry Balyasny | 5.09M | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Dames GP LLC | 5.09M | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Balyasny Asset Management Holdings LP | 5.09M | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Bam GP LLC | 5.09M | 10.0% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Balyasny Asset Management L.P. | 5.09M | 10.0% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Israel A. Englander | 3.43M | 5.1% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Millennium Group Management LLC | 3.43M | 5.1% | SCHEDULE 13G ↗ |
| May 1, 2026 | SCHEDULE 13G | SABS SAB Biotherapeutics, Inc. | Millennium Management LLC | 3.43M | 5.1% | SCHEDULE 13G ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 7.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Rajeev Shah | 7.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Peter Kolchinsky | 7.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 23, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Management, L.P. | 7.31M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Healthcare Fund, L.P. | 5.17M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Rajeev Shah | 5.17M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | Peter Kolchinsky | 5.17M | 9.9% | SCHEDULE 13D/A ↗ |
| Mar 11, 2026 | SCHEDULE 13D/A (amended) | SABS SAB Biotherapeutics, Inc. | RA Capital Management, L.P. | 5.17M | 9.9% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Roderick Wong | 1.59M | 3.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | RTW Investments, LP | 1.59M | 3.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | SABS SAB Biotherapeutics, Inc. | Mark N. Lampert | 4.76M | 9.1% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances